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Our previous reports showed that 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) has antiproliferative actions in
endothelial cells stably expressing viral G protein-coupled receptor (vGPCR) associated with the pathogenesis of
Kaposi's sarcoma. It has been reported that COX-2 enzyme, involved in the tumorigenesis of many types of
cancers, is induced by vGPCR. Therefore, we investigated whether COX-2 down-regulation is part of the growth
inhibitory effects of 1α,25(OH)2D3. Proliferation was measured in presence of COX-2 inhibitor Celecoxib (10–20
μM) revealing a decreased in vGPCR cell number, displaying typically apoptotic features in a dose dependent
manner similarly to 1α,25(OH)2D3. In addition, the reduced cell viability observed with 20 μM Celecoxib was
enhanced in presence of 1α,25(OH)2D3. Remarkably, although COX-2 mRNA and protein levels were up-regulated
after 1α,25(OH)2D3 treatment, COX-2 enzymatic activity was reduced in a VDR-dependent manner. Furthermore,
an interaction between COX-2 and VDR was revealed through GST pull-down and computational analysis.
Additionally, high-affinity prostanoid receptors (EP3 and EP4) were found down-regulated by 1α,25(OH)2D3.
Altogether, these results suggest a down-regulation of COX-2 activity and of prostanoid receptors as part of the
antineoplastic mechanism of 1α,25(OH)2D3 in endothelial cells transformed by vGPCR.1. Introduction
Kaposi's sarcoma (KS) is an angioproliferative disorder of vascular
endothelium and an AIDS-definingmalignancy. KS Herpesvirus (KSHV or
human herpesvirus-8) is the etiologic agent and Kaposi's sarcoma-
associated herpesvirus G protein-coupled receptor (vGPCR) is one of
the viral molecules from the lytic phase able to induce KS-associated
cellular modifications through paracrine oncogenesis [1, 2, 3]. In vivo
vGPCR induces angiogenic lesions similar to those developed in KS pa-
tients, showing powerful transforming properties [4]. Thus, vGPCR
signaling pathway is of great interest for KS treatment.lez-Pardo).
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is an open access article under tKSHV- infected human dermal microvascular endothelial cells
showed high expression of cyclooxygenase-2 (COX-2) [5, 6]. Shelby and
collaborators have reported increased COX-2 expression in primary
endothelial cells induced by vGPCR [7]. COX-2 catalyzes the conversion
of arachidonic acid to Prostaglandin H2 (PGH2) and, therefore, is the
responsible for the generation of prostaglandins (PGs), including Pros-
taglandin E2 (PGE2), a proliferation and inflammation-activating agent
[8]. COX-2 enzyme is up-regulated by mitogenic and inflammatory
stimuli, exerts pro-angiogenic and anti-apoptotic properties [9, 10], and
contributes to angiogenic progression of several cancers [10, 11].
Therefore, it is considered as a potential therapeutic target for preventingber 2020
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overexpression is associated with increased levels of prostanoids in tu-
mors, which exert their biological effects through GPCRs [12]. There are
four distinct E-type prostanoid EP receptors [13]; EP3 and EP4 represent
high-affinity receptors, whereas EP1 and EP2 require significantly higher
levels of PGE2 for activation [14].
The active form of Vitamin D, 1α,25(OH)2D3, is a steroid hormone
that plays a key role in calcium homeostasis. In addition, it has non-
classical effects in neoplastic cells by acting as an antiproliferative, pro-
apoptotic and pro-differentiating agent [15, 16]. Likewise, 1α,
25(OH)2D3 exerts anti-inflammatory properties through the inhibition of
pro-inflammatory cytokines and NF-κB signaling. Most of its actions
depend on VDR, the vitamin D nuclear receptor [17]. NF-κB pathway is
highly activated by vGPCR and we have shown that 1α,25(OH)2D3 pro-
motes NF-κB inhibition, consequently, apoptosis is induced in endothe-
lial cells that express vGPCR [18, 19]. It is known that inflammation
promotes cancer development and 1α,25(OH)2D3 has shown
anti-inflammatory properties in the carcinogenic microenvironments of
prostate, breast, colon and ovarian cancers [17, 20]. Since COX-2 is
induced in endothelial cells via vGPCR signaling [7], we investigated if
this key enzyme involved in the inflammatory response is
down-regulated by 1α,25(OH)2D3 as part of its mechanism of action.
2. Materials and methods
2.1. Chemicals and reagents
1α,25(OH)2D3, and the antibiotic G418 were from Sigma-Aldrich (St.
Louis, MO, USA). Puromycin was provided by Invivogen (San Diego, CA,
USA). The antibodies used were rat monoclonal anti-VDR (Affinity Bio-
reagents, Golden, CO, USA); mouse monoclonal anti-COX-2, anti-mouse
and anti-rat horseradish peroxidase–conjugated secondary antibody
(Santa Cruz, CA, USA). Roche Applied Science (Indianapolis, IN, USA)
provided high Pure RNA Isolation Kit. Immobilon P (polyvinylidene
difluoride; PVDF) membranes were from Thermo Scientific (Rockford, IL,
USA); PCR primers for mouse Gapdh, Cox-2, EP1, EP2, EP3 and EP4 were
synthetized by Invitrogen (Thermo Scientific Inc., Rockford, IL, USA).
Celecoxib (Santa Cruz, CA, USA). COX-2 Activity Assay kit (Cayman N
760151) was from Cayman Chemical Company (Michigan, USA).2.2. Cell lines and transfections
SV-40-immortalized murine endothelial cells stably expressing
vGPCR full length receptor (vGPCR), were utilized as the experimental
model of Kaposi's sarcoma previously described [21] and were kindly
donated by Dr. J. Silvio Gutkind (UCSD, San Diego, California, US).
vGPCR promotes tumor formation in immune-suppressed mice and in-
duces angiogenic lesions similar to those developed in Kaposi's sarcoma
when stably overexpressed [4, 21]. The expression of vGPCR was
routinely verified by qRT-PCR. 500 μg mL1 G418 were used to the se-
lection of transfected cells. Previously, by transduction of lentiviral
particles, stable vGPCR endothelial cells targeted with small hairpin RNA
against mouse VDR (vGPCR-shVDR) or control shRNA (vGPCR-shctrl)
were obtained and selected with 2 μg mL1 of puromycin [21]. Cells were
discarded after passage 10 andmedium was freshly changed every other
day. By Western blot analysis the VDR knock-down was monitored.Table 1. pdb structures for rat and mouse.
Rat Mouse
VDR 1RJK Modeled
COX-2 Modeled 3QMO2.3. Proliferation assays
vGPCR cells were cultured in 24-well plates, at a density of 4500 cells
per well. After overnight growth, the cells were starvedand then treated
with 1α,25(OH)2D3 (10 nM) or Celecoxib (10 or 20 μM) or control
(vehicle, 0.1% ethanol) in triplicate in DMEM 2% FBS for 48 h. Cells were
then counted in a Neubauer chamber. Dead cells were excluded using
trypan blue solution at 0.4%.2
2.4. MTS assays
vGPCR cells were seeded in 96-well plates at 1000 cells per well. After
overnight growth, cells were starved for 24 h and then treated with
1α,25(OH)2D3 (10 nM) or Celecoxib (10 μM) or vehicle (0.01% ethanol)
in triplicate in DMEM 2% FBS for 48 h. CellTiter 96® Aqueous one so-
lution cell proliferation assay containing 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium, inner salt
(MTS) was used to determine cell proliferation according to the manu-
facturer's instructions. Absorbance was measured at 490 nm.
2.5. COX-2 activity assay
COX activity was measured by COX-2 Activity Assay kit (Cayman N
760151) following the recommendations provided by the manufacturer.
In time response-experiments protein content fromwhole cell lysates was
determined by the Bradford procedure to standardize the signal detected
[22]. The product of the reaction was colorimetrically measured at 590
nm.
2.6. GST pull-down assay
To identify the interaction between COX-2 and VDR in vitro,
glutathione-S-transferase expression vectors were used. BL21 E. coli
transformed with PGEX4T3-GST or PGEX4T3-GST-VDR constructs were
induced to express GST or GST-VDR fusion proteins with 400 μM iso-
propyl β-D-thiogalactopyranoside [23, 24]. BL21 cells were centrifuged
and resuspended in 1 ml lysis buffer (20 mM Tris-HCl, pH 7.5, 100 mM
NaCl, 0.5 mM EDTA, 0.5% NP-40, 3 μg/ml lysozyme and protease in-
hibitors). The lysate was sonicated and pelleted by centrifugation for 10
min at 10000 rpm. Equal amounts of fusion proteins quantified by
Bradford procedure were incubated with glutathione-Sepharose beads
for 2 h with rotation at room temperature. After a centrifugation at 500 g
for 5 min the supernatant was discarded and the pellet containing
glutathione-Sepharose beads plus GST or GST-VDR was added to the
soluble fraction of vGPCR cell lysates and incubated for 2 h rotation at
room temperature. Beads were pelleted by centrifugation and eluted by
adding loading buffer for Western blot assay [25].
2.7. SDS-PAGE and Western blot
By the Bradford procedure the protein content from whole cell lysates
was determined [22]. Proteins were resolved with SDS–PAGE and
Western blot analyses were effected as reported before [22]. Antibodies
used include monoclonal mouse anti-COX-2 (1:500), rat anti-VDR
(1:6000), anti-mouse (1:5000) or anti-rat (1:5000) horseradish
peroxidase-conjugated secondary antibodies.
2.8. Quantitative real-time PCR
First, total RNA was isolated using the High Pure RNA Isolation Kit
(Roche). Then, RNA (0.5–1μg) reverse transcription was performed using
the kit High Capacity cDNA RT (Applied biosystem). qRT-PCR reactions
were performed on 5–10 ng of the resulting cDNA in an ABI 7500 Real
Time PCR system (Applied Biosystems, CA, USA). Specific primers to
detect Cox-2, EP1, EP2, EP3 and EP4 levels were used. Analysis of the real
time PCR data was executed by the 2-delta delta Ct method using Gapdh
as reference parameter [26]. Reactions were carried out using the SYBR
Figure 1. Inhibition of vGPCR cell growth by Celecoxib or 1α,25(OH)2D3. vGPCR cells were cultured and treated with 1α,25(OH)2D3 (1,25D) (10 nM) or Celecoxib
(10–20 μM) or vehicle (0.01% ethanol) (A) and (B) or 1α,25(OH)2D3 (1,25D) (10 nM) or Celecoxib (10 μM) or vehicle (0.01% ethanol) (C) in DMEM 2% FBS for 48 h.
A) Representative micrographs obtained by phase contrast microscopy, bar: 30 μm, magnification 200x. B) Cells were counted in Neubauer chamber. C) MTS assay was
performed. Results from at least three independent experiments, were presented in bar graphs. The statistical analysis was performed by one-way ANOVA followed by
the Bonferroni test. Significant differences are indicated by different letters (p < 0.01).
Figure 2. COX-2 mRNA rise is VDR dependent. vGPCR cells were cultured and treated with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) at different times
(0.3–48 h) (A) or stable vGPCR cells vGPCR-shVDR or control shRNA (vGPCR-shctrl) were treated with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) for 24 h (B);
in presence of DMEM 2% FBS. 1 μg of total RNA was extracted, reverse transcribed and gene expression of COX-2 and Gapdh was assessed by qRT-PCR analysis. Data
are expressed as a ratio between treated and vehicle samples at each time point and normalized to Gapdh mRNA levels. Data statistical significance from at least three
independent experiments was evaluated using Student's t-test (**p < 0.01) (A). Differences between control and treated conditions in vGPCR-shctrl or -shVDR group
and also treated conditions between vGPCR-shctrl and -shVDR were evaluated by Student's t-test (**p < 0.01) (B).
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quences used were:
Cox-2 forward: 50- TAGCAGATGACTGCCCAACT -30
Cox-2 reverse: 50- CAGGGATGAACTCTCTCCGT -30,
EP1 (Ptgdr1) forward: 50- CTAACCAAGAGTGCCTGGGA -30
EP1 (Ptgdr1) reverse: 50- GCTTCTGGGCACATTCAGAG -30
EP2 (Ptgdr2) forward: 50- CGATGCTCCTGCTGCTTATC -30
EP2 (Ptgdr2) reverse: 50- TGCATGCGAATGAGGTTGAG -30
EP3 (Ptgdr3) forward: 50- GGGATCATGTGTGTGCTGTC -30
EP3 (Ptgdr3) reverse: 50- GCATTGCTCAACCGACATCT -30
EP4 (Ptgdr4) forward: 50- TCTCTGGTGGTGCTCATCTG -30
EP4 (Ptgdr4) reverse: 50- GTCTTTCACCACGTTTGGCT -302.9. Computational analysis of protein-protein interaction
The electrostatic energy of interaction between the two proteins was
calculated solving the linear Poisson–Boltzmann equation. To this end,3
the software Adaptive Poisson-Boltzmann Solver (APBS) [27] was uti-
lized. This software was used to calculate the electrostatic energy of each
individual structure and of the complex formed by the two proteins.
Then, by calculating the difference between the complex and the indi-
vidual structures (Eq. (1)), electrostatic interaction energy was found.
EInteraction ¼EComplex  ðEProtein 1 þEProtein 2Þ (1)
This procedure was carried over the various possible orientations that
the proteins can adopt between each other. To be able to sample all the
possible configurations, an own-developed program was used. This
program generates all the necessary configurations by rotating the two
proteins around each other. First protein 1 was rotated around protein 2
so that protein 1 covered all possible positions along an imaginary sphere
around protein 2. Then, protein 1 was rotated around its own center, in
such a way that all possible orientations were sampled. Finally, the dis-
tance (r) between each final structure was set equal. This distance was
calculated by projecting all the coordinates of the two structures to the
axis defined by the center of both structures. Then, the minimumdistance
Figure 3. 1α,25(OH)2D3 increases COX-2 protein levels whereas decreases its activity on a VDR dependent manner. vGPCR cells were treated with 1α,25(OH)2D3
(10 nM) or vehicle (0.01% ethanol) for different times (0.5–48 h) (A), (B) and (C). Stable vGPCR cells vGPCR-shVDR or control shRNA (vGPCR-shctrl) were treated
with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) for 30 min (D). Cell lysates were subject to Western blot analysis with anti-COX-2 and anti-tubulin antibodies.
The representative blots are presented (A). The quantification of protein bands by densitometry was represented as the ratio between COX-2/Tubulin referred to
control in bar graphs (B). Peroxidase activity was measured colorimetrically with COX-2 Activity Assay kit (C) and (D). Statistical significance from at least three
independent experiments was evaluated using Student's t-test (**p < 0.01, *p < 0.05) (B) and (C). Differences between ctrl and treated conditions in vGPCR-shctrl or
-shVDR group and between treated conditions in vGPCR-shctrl and -shVDR group were analyzed by Student's t-test (**p < 0.01, *p < 0.05).
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¼ 10 Å. The program was written in Python and needs the structure of
both proteins in pqr format, which contains electric charge and Van der
Waals radius for each atom.
With that goal, reported pdb structures from two different species,
including Rat and Mouse were extracted from the PDBDataBank [28]
(PDB IDs: 1RJK and 3QMO), while unreported tertiary structure proteins
were modeled with homology model methods by funneling their primary
sequences through Swiss Model server [29, 30, 31, 32, 33] (Table 1).
Then, PDB2PQR [34] was used to obtain pqr files from pdb files. Finally,
the user must define the distance between the final orientations r, and the
size of the angular steps used when rotating. In this case all angular steps
where set to 45 and r ¼ 10 Å.2.10. Statistical analysis
Results presented as means  SD, were analyzed by one-way ANOVA
followed by Bonferroni test or two-tailed t-test to assess differences be-
tween control (vehicle) and treated (1α,25(OH)2D3) conditions at each
time (*p < 0.05 or **p < 0.01).
3. Results
3.1. Celecoxib reduces vGPCR cell number and viability
Previously we have demonstrated that 1α,25(OH)2D3 has anti-
proliferative effects on the growth of vGPCR cells [21]. Given that COX-2
expression is induced by vGPCR, we researched if COX-2 regulation
contributed to the inhibitory effect of 1α,25(OH)2D3. Proliferation assays
were analyzed by counting vGPCR cells in Neubauer chamber after
treatment with, 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) or4
Celecoxib (10–20 μM) in DMEM 2% fetal bovine serum (FBS) for 48 h.
Cellular morphological changes were observed by light field microscopy.
Cell viability was measured using the CellTiter 96® AQueous One Solution
Cell Proliferation Assay containing 3-(4,5-dimethylth-
ia-zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4
sulfophenyl)-2H-tetrazolium, inner salt (MTS). Results in Figure 1A and B
show that similar to 1α,25(OH)2D3, COX-2 inhibitor Celecoxib decreased
vGPCR cell number significantly in a dose-dependent manner, presenting
through the micrographs abnormal shrinking and rounding, typical
apoptotic alterations. Results in Figure 1C indicate that cell viability was
diminished by 1α,25(OH)2D3 or Celecoxib (10 μM) and no further effect
was observed when both agents were used in combination.3.2. Cox-2 mRNA is up-regulated by 1α,25(OH)2D3 in a VDR dependent
mechanism
There are many reports showing the anti-inflammatory action of
1α,25(OH)2D3 through the inhibition of COX-2 expression [20, 35, 36].
On the other hand, some data demonstrated vitamin D induces COX-2
expression in epithelial cells [37, 38] Therefore Cox-2 mRNA levels
were evaluated by qRT-PCR at different time points (0.3–48 h) after 1α,
25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) treatments in presence of
DMEM 2% FBS. Results presented in Figure 2A show an increased
expression of Cox-2 mRNA induced by 1α,25(OH)2D3. To evaluate if this
rise was dependent of VDR, vGPCR cells targeted with small hairpin RNA
against mouse VDR (vGPCR-shVDR) or control shRNA (vGPCR-shctrl)
were treated with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) in
presence of DMEM 2% FBS for 24 h. Effectively, the increase in COX-2
mRNA expression after 1α,25(OH)2D3 treatment was VDR dependent
(Figure 2B).
Figure 4. COX-2 and VDR interaction. Computa-
tional analysis of protein-protein interaction is shown.
Electrostatic energy versus different configurations of
VDR–COX2 complex. 3872 relative positions were
evaluated. The starting point is a random position, but
always the same. For clarity, angles degree variations
were no labeled. Curves with different colors indicate
VDR–COX2 complex from different species. Grey for
Rat and black for Mouse (A). View of Mouse VDR-
COX2 complex in the configuration of minimum en-
ergy. Left in black: putative mouse VDR leading re-
gions. Right in black: putative mouse COX2 leading
regions (B). Protein content from vGPCR cell lysates
was incubated with BL21 pellet containing
glutathione-Sepharose beads plus GST or GST-VDR.
After centrifugation beads were eluted with loading
buffer for Western blot assay with anti-COX-2 and
anti-VDR antibodies. Representative blots from three
experiments are shown (C).
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To further characterize COX-2 regulation by 1α,25(OH)2D3, we
investigated COX-2 protein levels using Western blot. vGPCR cells were
treated with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) in DMEM
2% fetal bovine serum (FBS) for different times (0.5–48 h). The results in
Figure 3A show representative blots of a significant increase in COX-2
expression after treatment from 6 h onwards. Figure 3B shows the
quantification of the bands from at least three independent experiments.
Next, the regulation on COX-2 activity was investigated. vGPCR cells
were treated with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) in
DMEM 2% fetal bovine serum (FBS) for different times (0.5–48 h).
Peroxidase activity was measured colorimetrically with a COX-2 Activity
Assay kit (Cayman N 760151). The results in Figure 3C indicate that
COX-2 activity was rapidly but transiently reduced by 1α,25(OH)2D3
treatment and stabilized at longer periods. To evaluate a connection
between VDR and the reduced activity of COX-2 enzyme, a VDR knock-
down cellular model was used to measure COX-2 activity at one of the
time points where its activity was significantly reduced. vGPCR cells,
vGPCR-shVDR or control shRNA (vGPCR-shctrl), were incubated with
1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) in DMEM 2% FBS for5
30 min. Results presented in Figure 3D demonstrate that COX-2 activity
is higher in treated conditions were VDR is knockdown, hence reduced
activity after 1α,25(OH)2D3 treatment depends on VDR.3.4. VDR interacts with COX-2
Although COX-2 gene and protein levels are increased after
1α,25(OH)2D3 treatment, the enzymatic activity decreases rapidly in a
VDR-dependent manner. Therefore, to elucidate how these events are
linked, we tested the hypothesis of a potential VDR and COX-2 interac-
tion. We first examined by in silico studies the electrostatic energy of the
potential binding between VDR and COX-2 in two different species. For
rat VDR-COX-2 interaction, the electrostatic energy landscape showed
grouped significant minimum values as expected in a favorable interac-
tion for this method [39, 40, 41]. In this case, Lys123-GLU127 and
ALA345-PRO368 residues from VDR seem to lead the orientation in the
interaction by pointing to the GLU402-ARG414 and SER552- GLN569
regions of COX-2. For mouse VDR-COX-2 interaction, some appreciable
minimum values were found, although they were not as clustered nor as
marked as for rat VDR-COX-2 interaction. Similar to the rat electrostatic
interaction landscape, minimum values occurred for relative positions in
Figure 5. EPs mRNA expression is regulated by 1α,25(OH)2D3. vGPCR cells
were incubated with 1α,25(OH)2D3 (10 nM) or vehicle (0.01% ethanol) in
DMEM 2% FBS for 24–48 h. 1 μg of total RNA was extracted, and reverse
transcribed. qRT-PCR was used to analyze gene expression of EP1, EP2, EP3, EP4
and Gapdh. Results are expressed as a ratio between treated and vehicle con-
ditions normalized to Gapdh mRNA levels. The statistical significance of data
from at least three independent experiments was analyzed by Student's t-test
(**p < 0.01, *p < 0.05).
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ingly lead the orientation in the interaction by pointing towards the
THR394-GLN429 region of COX-2 (Figure 4A). To confirm these data, we
evaluated a possible interaction among VDR and COX-2 by
GST-pull-down assay. Total lysates from vGPCR cells were incubated
with GST-VDR or GST glutathione-Sepharose beads obtained from pre-
viously transformed E. coli BL21, respectively. To determine VDR/COX-2
interaction after incubation proteins were analyzed by Western Blot. As
shown in Figure 4C, COX-2 co-precipitates with GST-VDR. These results
argue in favor of an interaction between COX-2 and VDR.
3.5. 1α,25(OH)2D3 regulates EPs mRNA expression
The COX-2 dysregulation leads to elevated levels of PGE2, which acts
locally in an autocrine or paracrine manner through four pharmaco-
logically distinct G-protein coupled plasma membrane receptors, EP1,
EP2, EP3 and EP4. Each one can activate different downstream signaling
pathways [14]. To investigate if 1α,25(OH)2D3 changes the expression
levels of EPs receptors when COX-2 activity turns to stable levels,
vGPCR cells were incubated with 1α,25(OH)2D3 (10 nM) or vehicle
(0.01% ethanol) in DMEM 2% FBS for 24–48 h. Total RNA was isolated
and reverse transcribed followed by qRT-PCR using specific primers to
detect EP1, EP2, EP3 and EP4 mRNA levels and Gapdh mRNA was used
to normalize gene expression. The results presented in Figure 5 indicate
that high-affinity receptors EP3 and EP4 are down-regulated; never-
theless, EP1 and EP2 low-affinity receptors behave differently. EP1 di-
minishes it expression at 48 h but EP2 mRNA levels are higher. These
results present a differential suppression of PGE2 biological activity by
1α,25(OH)2D3.
4. Discussion
1α,25(OH)2D3, the biologically-active form of vitamin D, exerts
antiproliferative and pro-differentiating actions on cancer cells [20].
Most of its actions depend on VDR [17]. There is evidence that 1α,
25(OH)2D3 has anti-inflammatory effects through the inhibition of
COX-2 expression [35, 36]. COX or prostaglandin-endoperoxide synthase
is the enzyme that catalyzes the conversion of arachidonic acid (AA) into
prostaglandin H2, which is converted into proinflammatory lipid me-
tabolites like PGE2, an inflammation-activating agent [8, 42].
Since COX-2 plays a key role in prostanoids production and inflam-
mation, and is highly activated by vGPCR in Kaposi's sarcoma [7], it6
raises the question whether the antiproliferative effects of 1α,25(OH)2D3
on vGPCR could be caused in part to COX-2 down-regulation. Our find-
ings demonstrated that the inhibition of COX-2 with Celecoxib reduced
the proliferation of endothelial cells transformed by vGPCR like 1α,
25(OH)2D3 (Figure 1). As no additive effect was observed when both
agents were incorporated together, it implies that the hormone and
Celecoxib could act by the same mechanism. However, time response
studies showed COX-2 mRNA and protein levels increased after 1α,
25(OH)2D3 treatment (Figures 2A and 3A), moreover, this expression rise
was VDR dependent (Figure 2B). Consequently, we measured the
peroxidase activity of COX-2 in vGPCR cells and we found a low activity
after 1α,25(OH)2D3 treatment for short periods of time that stabilized
itself later (Figure 3B). This effect was VDR-dependent (Figure 3C)
indicating a connection between COX-2 and VDR responsible for this
high expression with diminished activity. Regarding to the electrostatic
interaction results, even though the unavailability of a complete tridi-
mensional structure for two of the proteins studied showed not conclu-
sive interactions between VDR and COX-2, the performed test was
informative. According to the results obtained from the electrostatic
analyses from rat and mouse VDR-COX-2 interactions, similar regions of
these proteins could be involved in leading the interaction (Figure 4A and
B). Next, GST-Pull Down results exposed an interaction between COX-2
and VDR that supported the previous electrostatic analysis (Figure 4C)
and provided evidence for an interaction between COX-2 and VDR.While
COX-2 is generally expressed in the cytoplasm, studies have indicated
perinuclear localization [43] and trafficking between the nucleus and the
cytoplasm in endothelial cells [44] affecting nuclear events, data that
supports the plausibility of an interaction between COX-2 and VDR in
intact cells.
On the other hand, one of the main products of COX-2 catalyzed re-
actions is PGE2, which performs its inflammatory actions through four G-
protein couple receptors. Each of these EPs receptors can activate
different downstream signaling pathways making PGE2 able to mediate
highly varied effects on different types of cells [14]. Previous reports
indicated that COX-2 increases PGE2 production in HUVEC cells
expressing vGPCR [7]. Moreover, 1α,25(OH)2D3 decreases PGE2 secre-
tion and represses EPs mRNA expression in prostate cancer cells, regu-
lating PGs metabolism and biological actions [45]. In this work, we
showed that high-affinity receptors EP3 and EP4 are down regulated
after 1α,25(OH)2D3 treatment, on the contrary, EP1 and EP2 low-affinity
receptors which require significantly higher levels of PGE2 for activation
behave differently. EP1 diminishes it expression at 48 h but EP2 mRNA
levels are higher (Figure 5). Both the EP2 and EP4 receptors are con-
nected to G-stimulatory (Gαs) proteins, which through adenylate cyclase
activation increase cAMP cell levels that leads to the activation of PKA or
the GSK3β/β-catenin pathway. Consequently, despite being linked to the
same G protein, the different affinity to PGE2 shows a differential sup-
pression for EPs receptors' expression. There are reports of an autocrine
PGE2 positive feedback involving EP2 and EP4 to induce COX-2 pro-
duction [46, 47], this reinforced mechanism due to the diminish pro-
duction of PGE2 could explain COX-2 low activity with a high expression.
In conclusion, despite more studies are needed to elucidate the effect
of 1α,25(OH)2D3 in PGE2 biological activity, these results demonstrate
that 1α,25(OH)2D3 antiproliferative effects on vGPCR cells could be
caused by a down regulation of PGE2 production through the interaction
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